vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
![VBI Vaccines logo](/files/LOGO/764195-VBIV.png)
Company profile
Ticker
VBIVQ
Exchange
Website
CEO
Jeffrey R. Baxter
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.
SEC CIK
Corporate docs
Subsidiaries
VBI Vaccines (Delaware) Inc. • SciVac Ltd. • Variation Biotechnologies (US), Inc. • Variation Biotechnologies Inc. • SciVac Hong Kong Limited ...
VBIVQ stock data
Latest filings (excl ownership)
8-K
VBI Vaccines Provides an Update on its Restructuring Proceedings
2 Aug 24
8-K
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
30 Jul 24
8-K
VBI Vaccines Announces Results of Annual General Meeting
25 Jun 24
8-K
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
29 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 May 24
8-K
VBI Vaccines Reports First Quarter 2024 Financial Results
15 May 24
424B5
Prospectus supplement for primary offering
15 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Other Events
1 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
Latest ownership filings
SC 13D/A
PERCEPTIVE ADVISORS LLC
17 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
20 Nov 23
4
Michel DeWilde
31 Jul 23
4
Damian Braga
31 Jul 23
4
Jeff Baxter
28 Jul 23
4
Joanne Cordeiro
28 Jul 23
4
Nell Beattie
28 Jul 23
4
VAUGHN B HIMES
28 Jul 23
4
Avi Mazaltov
28 Jul 23
4
Francisco Diaz-Mitoma
28 Jul 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
52.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 4 |
Closed positions | 54 |
Increased positions | 1 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 6.73 bn |
Total shares | 15.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Arch Venture Fund Vi | 13.03 mm | $15.96 mm |
Perceptive Advisors | 1.38 mm | $4.54 bn |
BLK BlackRock | 112.15 k | $368.96 mm |
Cambridge Investment Research Advisors | 100.37 k | $330.00 k |
Millennium Management | 89.21 k | $293.48 mm |
MS Morgan Stanley | 77.98 k | $256.55 mm |
Geode Capital Management | 67.19 k | $221.05 mm |
Vanguard | 62.63 k | $206.06 mm |
GAM General American Investors | 62.58 k | $205.90 mm |
Y-Intercept | 39.77 k | $130.85 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jul 23 | Baxter Jeff | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 70,000 | 91.00 k | 70,000 |
27 Jul 23 | Joanne Cordeiro | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 35,000 | 45.50 k | 35,000 |
27 Jul 23 | Beattie Nell | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 52,500 | 68.25 k | 52,500 |
27 Jul 23 | Michel DeWilde | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 35,000 | 45.50 k | 35,000 |
27 Jul 23 | Anderson David Evander | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 52,500 | 68.25 k | 52,500 |
News
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
7 Aug 24
Dow Jumps Over 300 Points; US Trade Gap Narrows In June
6 Aug 24
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
5 Aug 24
Dow Tumbles 950 Points; ISM Services PMI Surges In July
5 Aug 24
Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views
5 Aug 24